Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00341172
Other study ID # 999905023
Secondary ID 05-C-N023
Status Completed
Phase
First received
Last updated
Start date October 26, 2004
Est. completion date March 4, 2021

Study information

Verified date March 2021
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will evaluate the role of certain gene variants on the onset and course of cytomegalovirus (CMV) retinitis-a severe infection affecting the eye-in patients with AIDS. Symptoms include blurry vision, eye pain, photophobia, floaters, eye redness, and impaired vision. Left untreated, it can cause blindness. The study is done in collaboration with investigators of the Longitudinal Studies of the Ocular Complications of AIDS (LSOCA) at the Johns Hopkins University School of Medicine. The purpose of the LSOCA study is to learn about how HIV and other infections associated with AIDS and their treatments affect people's eyes and sight. Blood samples previously collected from patients participating in the LSOCA study will be analyzed for gene variants. These differences will then be correlated with the patients' clinical data to try to discover the role of gene differences among patients on the following: susceptibility to CMV and related problems; development and course of CMV; and response to HAART (highly active antiretroviral treatment), particularly in CMV onset and pathology. The study will use blood samples and clinical information previously collected from patients during their participation in LSOCA. The materials will be identified with a numerical code linking the samples and clinical data. No additional procedures will be performed on patients for this study.


Description:

Background: LSOCA is a prospective observational study of ocular complications in HIV-infected AIDS patients including those treated with highly active anti-retroviral treatment (HAART). In the absence of HAART, there is a 30% risk of cytomegalovirus (CMV0 infection associated with AIDS. Of these CMV patients, 75-85% will develop retinitis. Objectives: Test a number of human candidate gene polymorphisms in the LSOCA cohort samples to discover genetic influences on the susceptibility to CMV and associated pathologies. Inspect the role of known AIDS restriction genes (ARGs) on the infection and pathogenesis of CMV. Evaluate the role of the same host gene polymorphisms on the response to HAART, particularly in CMV onset and pathology. Eligibility: Lymphocytes for DNA extraction and relevant clinical data from properly consented AIDS patients (maximum estimated at n= 2,000) will be provided to the LGD for genotyping and analysis. No available subjects will be excluded. Design: LSOCA has collected blood specimens and banked viably frozen lymphocytes from each study participant. Samples and clinical data are coded and linked. Genes under study include the traditional described ARGs (O'Brien & Nelson, 2004); the CMV receptor gene, US28 (Pleskoff et al., 1997); HLA class I and II; KIR gene family and other genes involved in virus immune defenses. Single nucleotide variants within coding regions, upstream and downstream regulatory regions, and ironic elements will be tested for genetic equilibrium distortion in patient populations at risk for CMV and displaying CMV pathology. Following this study, the samples will be maintained in our repository and curated through our central Laboratory database. Loss or destruction of these samples will be recorded in our database and cannot impact the study participants in any way. We understand that studies subsequent to the completion of this protocol will require additional OHSR/IRB approval prior to commencement.


Recruitment information / eligibility

Status Completed
Enrollment 2232
Est. completion date March 4, 2021
Est. primary completion date June 30, 2011
Accepts healthy volunteers No
Gender All
Age group 13 Years to 100 Years
Eligibility - INCLUSION CRITERIA: Lymphocytes for DNA and relevant clinical data from properly consented subjects will be provided to the LGD for genotyping and analysis. No available subjects will be excluded. Diagnosis of AIDS according to the 1993 CDC diagnostic criteria (with or without clinical symptoms of CMV retinitis or other ocular complications of AIDS). Age 13 years or older Signed consent statement For minors, ages 13-17, signed Consent Statement (by parent/guardian) and Assent Statement (by adolescent and parent/guardian).

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Johns Hopkins University Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Jabs DA, Van Natta ML, Kempen JH, Reed Pavan P, Lim JI, Murphy RL, Hubbard LD. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2002 Jan;133(1):48-61. — View Citation

O'Brien SJ, Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev. 2000 Oct;177:99-111. Review. — View Citation

O'Brien SJ, Nelson GW, Winkler CA, Smith MW. Polygenic and multifactorial disease gene association in man: Lessons from AIDS. Annu Rev Genet. 2000;34:563-591. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Collection of 2500 samples this study is complete Annually
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Not yet recruiting NCT03661203 - Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
Completed NCT02711878 - Healing Hearts and Mending Minds in Older Adults Living With HIV N/A
Completed NCT02606344 - Effect of a Micro-finance-based Intervention for the Prevention of Intimate-partner Violence and HIV N/A
Completed NCT01348308 - Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients Phase 3
Completed NCT01053598 - Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting N/A
Completed NCT01237366 - Study Targeting Affect Regulation Phase 1/Phase 2
Withdrawn NCT00951795 - Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts N/A
Completed NCT00740389 - TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects. Phase 1
Withdrawn NCT00347750 - Pharmacokinetics and Pharmacodynamics of an Anti-HIV Drug in Israeli Ethiopian and Non-Ethiopian Populations Phase 3
Completed NCT00317460 - Buprenorphine and Integrated HIV Care Phase 4
Withdrawn NCT00340223 - HLA-B35 Alleles and AIDS N/A
Completed NCT00144352 - In-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Adults Phase 4
Completed NCT01084395 - Reducing HIV Risk Among Mexican Youth N/A
Completed NCT00202241 - The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS N/A
Recruiting NCT06145841 - Metagenomic Next-Generation Sequencing Guides Anti-Infection Strategies
Completed NCT03633721 - Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women Phase 2
Completed NCT04567693 - Reducing Time to Spaced-out Appointments for Newly-diagnosed People Living With HIV N/A
Completed NCT03023033 - Supporting Attendance for Facility Delivery and Infant Health N/A
Recruiting NCT02162797 - Zinc Supplementation Effect on Immune Recovery in HIV Patients N/A